Vutrisiran, an investigational therapy for familial amyloid polyneuropathy (FAP), eased neurological impairments, lessened heart stress, and ameliorated quality…
Articles by Steve Bryson, PhD
Novo Nordisk has acquired Prothena’s clinical-stage antibody PRX004, an investigational therapy for people with hereditary transthyretin amyloidosis (ATTR),…
Living with hereditary transthyretin amyloidosis (hATTR), a group of rare disorders that includes familial amyloid polyneuropathy (FAP), affects the…
Editor’s note: The Amyloidosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Nerve function deteriorates more rapidly in people with familial amyloid polyneuropathy (FAP) than…
Intellia Therapeutics anticipates reporting interim data this year from a Phase 1 study evaluating the…
Symptoms related to familial amyloid polyneuropathy (FAP) and other forms of hereditary transthyretin…
Benzbromarone (BBM), a medicine used to treat gout, can stabilize the TTR protein to the…
Onpattro (patisiran) is more effective than Tegsedi (inotersen) at reducing neurological…
Tegsedi (inotersen) continued to slow disease progression and improve the quality of life in people…